{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:16:14Z","timestamp":1775747774637,"version":"3.50.1"},"reference-count":23,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Clazosentan prevents vasospasms after aneurysmal subarachnoid hemorrhage (SAH). However, clinical data on patients with SAH with ruptured vertebral artery dissecting aneurysms (VADAs) are limited. We report the case of a 49-year-old male patient with mild-grade (WFNS grade 1) thick and diffuse (modified Fisher grade 3) SAH who underwent endovascular trapping of a ruptured VADA, resulting in a poor functional outcome with a modified Rankin Scale score of 4 due to severe symptomatic vasospasm refractory to clazosentan, requiring repeated rescue endovascular therapies and chronic communicating hydrocephalus. A retrospective analysis of the clot density in the basal and Sylvian cisterns, assessed by the Hounsfield unit (HU) values of serial CT scans, in this patient showed persistent higher values, distinct from another VADA case that showed a decline in HU values with a good clinical course. These results imply the limited effectiveness of clazosentan in cases of thick and diffuse SAH after a ruptured VADA, even in good-clinical-grade patients treated with less invasive modalities. The HU values may become a simple quantitative marker for predicting symptomatic vasospasms and chronic hydrocephalus.<\/jats:p>","DOI":"10.3390\/medicina60091543","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T10:49:48Z","timestamp":1726829388000},"page":"1543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Symptomatic Vasospasm Refractory to Clazosentan after Subarachnoid Hemorrhage of Ruptured Vertebral Artery Dissecting Aneurysm: Clinical Implications from Two Contrasting Cases"],"prefix":"10.3390","volume":"60","author":[{"given":"Yasuyuki","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-379X","authenticated-orcid":false,"given":"Tatsushi","family":"Mutoh","sequence":"additional","affiliation":[{"name":"Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"},{"name":"Department of Aging Research and Geriatric Medicine, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junta","family":"Moroi","sequence":"additional","affiliation":[{"name":"Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jocn.2011.03.034","article-title":"Management of ruptured and unruptured intracranial vertebral artery dissecting aneurysms","volume":"18","author":"Su","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.wneu.2021.05.018","article-title":"Subarachnoid hemorrhage due to rupture of vertebral artery dissecting aneurysms: Treatments, outcomes, and prognostic factors","volume":"152","author":"Korai","year":"2021","journal-title":"World Neurosurg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1227\/00006123-199505000-00003","article-title":"Recurrent subarachnoid hemorrhage from untreated ruptured vertebrobasilar dissecting aneurysms","volume":"36","author":"Mizutani","year":"1995","journal-title":"Neurosurgery"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.clineuro.2009.07.008","article-title":"Successful endovascular reconstruction of acutely ruptured pseudoaneurysm of the vertebral artery, complicated by isolated vertebrobasilar circulation and symptomatic vasospasm","volume":"111","author":"Khan","year":"2009","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1227\/neu.0000000000002601","article-title":"Efficacy and safety of clazosentan after aneurysmal subarachnoid hemorrhage: An updated meta-analysis","volume":"93","author":"Pontes","year":"2023","journal-title":"Neurosurgery"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3171\/2022.2.JNS212914","article-title":"Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: Two randomized phase 3 trials in Japanese patients","volume":"137","author":"Endo","year":"2022","journal-title":"J. Neurosurg."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sakata, H., Kanoke, A., Uchida, H., Haryu, S., Omodaka, S., Kimura, N., Yoshida, M., Niizuma, K., Tominaga, T., and Endo, H. (2024). Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: A single-center retrospective cohort study. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1413632"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jocn.2024.06.019","article-title":"The effectiveness and safety of clazosentan in treating aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis","volume":"126","author":"Saha","year":"2024","journal-title":"J. Clin. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3171\/2020.3.JNS193400","article-title":"Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage","volume":"134","author":"Aldrich","year":"2021","journal-title":"J. Neurosurg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e943303","DOI":"10.12659\/MSM.943303","article-title":"Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center","volume":"30","author":"Mutoh","year":"2024","journal-title":"Med. Sci. Monit."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mutoh, T., Aono, H., Seto, W., Kimoto, T., Tochinai, R., Moroi, J., and Ishikawa, T. (2024). Cardiopulmonary Events of the Elderly (\u226575 Years) during Clazosentan Therapy after Subarachnoid Hemorrhage: A Retrospective Study from a Tertiary Stroke Center in Japan. Medicina, 60.","DOI":"10.3390\/medicina60010185"},{"key":"ref_12","first-page":"e54850","article-title":"Successful Fluid Management in Respiratory Failure due to Clazosentan Following a Cerebral Aneurysm Clipping: A Case Report","volume":"16","author":"Kinoshita","year":"2024","journal-title":"Cureus"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10143-023-02104-2","article-title":"Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: A multicenter retrospective cohort study","volume":"46","author":"Muraoka","year":"2023","journal-title":"Neurosurg. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10143-024-02345-9","article-title":"Comparison of efficacy between clazosentan and fasudil hydrochloride-based management of vasospasm after subarachnoid hemorrhage focusing on older and WFNS grade V patients: A single-center experience in Japan","volume":"47","author":"Mochizuki","year":"2024","journal-title":"Neurosurg. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.wnsx.2023.100253","article-title":"Initial real-world experience of clazosentan for subarachnoid hemorrhage in Japan","volume":"21","author":"Maeda","year":"2024","journal-title":"World Neurosurg. X"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.21037\/qims-23-355","article-title":"Hounsfield unit as a predictor of symptomatic vasospasm and hydrocephalus in good-grade subarachnoid hemorrhage treated with endovascular coiling","volume":"13","author":"Park","year":"2023","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: Explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"J. Clin. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7461\/jcen.2016.18.3.201","article-title":"Endovascular Treatment of Symptomatic Vertebral Artery Dissecting Aneurysms","volume":"18","author":"Han","year":"2016","journal-title":"J. Cerebrovasc. Endovasc. Neurosurg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1161\/STROKEAHA.114.004739","article-title":"Early intensive versus minimally invasive approach to postoperative hemodynamic management after subarachnoid hemorrhage","volume":"45","author":"Mutoh","year":"2014","journal-title":"Stroke"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1161\/STROKEAHA.119.025682","article-title":"Thick and diffuse subarachnoid blood as a treatment effect modifier of clazosentan after subarachnoid hemorrhage","volume":"50","author":"Mayer","year":"2019","journal-title":"Stroke"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1016\/j.wneu.2019.04.222","article-title":"Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study","volume":"128","author":"Higashida","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41467-024-46015-2","article-title":"Diagnosis and management of subarachnoid haemorrhage","volume":"15","author":"Thilak","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2024.4.JNS232191","article-title":"REACT: A randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage","volume":"1","author":"Mayer","year":"2024","journal-title":"J. Neurosurg."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/9\/1543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:01:10Z","timestamp":1760112070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/9\/1543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["medicina60091543"],"URL":"https:\/\/doi.org\/10.3390\/medicina60091543","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]}}}